23 citations
,
March 2017 in “PTR. Phytotherapy research/Phytotherapy research” Butin is effective in treating vitiligo in mice.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
September 2023 in “Journal of the American Academy of Dermatology” 39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
84 citations
,
September 2008 in “Developmental biology” Retinoic acid-binding proteins in skin are regulated by β-catenin and Notch signalling.
1 citations
,
October 2024 in “Journal of King Saud University - Science” Tridax procumbens extracts may help treat cancer due to their strong anticancer and antioxidant properties.
83 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
1 citations
,
December 2021 in “JAAD case reports” A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
20 citations
,
September 1983 in “Archives of dermatology” The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
6 citations
,
August 2024 in “Advanced Science” A new method efficiently creates biaryl N-oxides with potential for cancer treatment and drug development.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
October 2024 in “Media Farmasi” Combining soursop leaf extract with doxorubicin may improve breast cancer treatment and reduce side effects.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
July 2025 in “International Journal of Trichology” Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
August 2025 in “Pharmaceutics” A new method improves betulin delivery and shows promise in cancer treatment.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
29 citations
,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
39 citations
,
January 2015 in “Cochrane library” Chemotherapy may help with survival in children with medulloblastoma, but more research is needed.
February 2023 in “Reactions Weekly” 3 citations
,
July 2025 in “British Journal of Dermatology” Cinainu is effective and safe for treating children's alopecia areata.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.